ArQule, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs target biological pathways implicated in a range of cancers and certain non-oncology indications. Its product candidates and programs are based on biological processes that lead to the proliferation and metastasis of cancer cells, combined with generating product candidates possessing certain pre-selected, drug-like properties. Its lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. The Company's product candidates include ARQ 092, ARQ 087, ARQ 751 and ARQ 761.